Literature DB >> 10616633

Cognitive disability and direct care costs for elderly people.

S Kavanagh1, M Knapp.   

Abstract

BACKGROUND: Population ageing and the high costs of care support for elderly people have concentrated attention on economic issues. Is there an association between costs and cognitive disability? AIMS: To compare service utilisation and direct costs for elderly people with different degrees of cognitive disability, and between people living in households and in communal establishments.
METHOD: Secondary analysis of Office of Population Censuses and Surveys (OPCS) Disability Surveys data compared service utilisation and costs for 8736 elderly people with cognitive disability. Cost estimates were constructed for all health and social care services.
RESULTS: A much greater proportion of people at higher levels of cognitive disability lived in communal establishments, where their (direct) costs were much higher than when supported in households. Service utilisation patterns and costs varied with cognitive disability.
CONCLUSIONS: It is important to look at the full range of living arrangements and support services when examining costs. The potential cost implications of pharmacotherapies, other treatments or new care arrangements cannot be appreciated without such a broad perspective.

Entities:  

Mesh:

Year:  1999        PMID: 10616633     DOI: 10.1192/bjp.174.6.539

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  6 in total

Review 1.  Alzheimer's disease: the strength of association of costs with different measures of disease severity.

Authors:  J Mauskopf; J Racketa; E Sherrill
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

2.  Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.

Authors:  Nick Bosanquet; Andrew Yeates
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 3.  A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease.

Authors:  Joanna Kirby; Colin Green; Emma Loveman; Andrew Clegg; Joanna Picot; Andrea Takeda; Elizabeth Payne
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 4.  Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease.

Authors:  Linus Jönsson
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

5.  Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial.

Authors:  Jackie F Price; Marlene C Stewart; Ian J Deary; Gordon D Murray; Peter Sandercock; Isabella Butcher; F Gerald R Fowkes
Journal:  BMJ       Date:  2008-09-01

6.  What are the benefits of cognitive enhancers for Alzheimer's Disease: use of Population Impact Measures.

Authors:  Udaya P Gammanpila; Alistair Burns; Richard F Heller; Nitin Purandare
Journal:  BMC Geriatr       Date:  2007-11-06       Impact factor: 3.921

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.